Dietary influence on pancreatic cancer growth by catechin and inositol hexaphosphate.
Level 5 - mechanism / opinion, no new human data
In vitro cell culture study with no human or animal subjects
PubMed 17574044 · doi:10.1016/j.jss.2007.03.065
What was done
Pancreatic cancer cell lines (PANC-1 and MIAPACA) were cultured and treated with inositol hexaphosphate (IP6, 0.8 mM/well), catechin (100 µM/well), or both in combination. Cell viability was measured by MTT assay at 24, 48, and 72 hours. Apoptosis was assessed using Annexin V-FITC staining, and vascular endothelial growth factor (VEGF) secretion in cell supernatants was measured by ELISA.
What was found
In PANC-1 cells, the combination of catechin and IP6 inhibited proliferation significantly more than either agent alone at 24, 48, and 72 hours (P < 0.001). In MIAPACA cells, each agent alone inhibited growth (P < 0.01), but no additive effect was observed with the combination. Catechin increased early apoptosis in both cell lines (P < 0.01), and the combination increased early apoptosis relative to control (P < 0.001). IP6 reduced VEGF secretion in both cell lines (P < 0.01), and the combination further amplified VEGF reduction compared to individual agents in MIAPACA and control (P < 0.002). Exact percentage changes or baseline values were not reported in the abstract.
Why it matters
This study provides preliminary cell-culture evidence that combining tea-derived catechin and dietary IP6 can exert anti-proliferative and anti-angiogenic effects in pancreatic cancer models.
Limits
The study is restricted entirely to in vitro cell lines and does not provide in vivo pharmacokinetics, bioavailability, or clinical efficacy data. Quantitative baseline and post-treatment values (percentages or concentrations) were not provided in the abstract.
Cited by
- context The compound IP6 was too toxic when tested in clinical settings and animal models for pancreatic cancer, but became non-toxic and therapeutically synergistic when combined with metabolic therapy.